Related Experiment Video

Updated: Jul 13, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression

Tom Johnstone1, Carien M van Reekum, Heather L Urry

  • 1Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin-Madison, Madison, Wisconsin 53705, USA. itjohnstone@wisc.edu

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|August 19, 2007
PubMed

Insights

Major depressive disorder (MDD) involves impaired mood regulation. Brain imaging reveals depressed individuals fail to engage key prefrontal cortex circuits for downregulating negative emotions, unlike healthy individuals.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cognitive Psychology

Background:

  • Depressed mood is a normal response to adversity, but major depressive disorder (MDD) is characterized by an inability to regulate negative mood.
  • Understanding the neural basis of emotion regulation is crucial for deciphering the pathophysiology of depression.

Purpose of the Study:

  • To investigate the neural underpinnings of adaptive emotion regulation in individuals with and without major depressive disorder (MDD).
  • To identify how emotion regulation processes are compromised in MDD.

Main Methods:

  • Functional magnetic resonance imaging (fMRI) was used to examine brain activity during emotion regulation tasks.
  • Participants performed an affective reappraisal task involving downregulating negative affect.
  • Pupil dilation was measured to assess effortful emotion regulation.

Main Results:

  • Nondepressed individuals showed left-lateralized prefrontal cortex (PFC) activation when downregulating negative affect, with an inverse relationship between left ventrolateral PFC and amygdala activation, mediated by ventromedial PFC (VMPFC).
  • Depressed individuals exhibited bilateral PFC activation and a positive association between VMPFC and amygdala activation, indicating a lack of effective top-down regulation.
  • Pupil dilation data indicated that increased effort in reappraisal by depressed individuals correlated with heightened amygdala, insula, and thalamus activation, contrasting with nondepressed individuals.

Conclusions:

  • Major depressive disorder (MDD) is associated with a failure to engage adaptive emotion regulation circuitry, specifically the left lateral-ventromedial prefrontal cortex pathway.
  • Counterproductive engagement of the right prefrontal cortex and impaired downregulation of amygdala responses are key features in the pathophysiology of depression.
  • These neural differences highlight distinct mechanisms of emotion regulation in MDD, offering targets for therapeutic interventions.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

Related Concept Videos

Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...